Clinical Trials in Minneapolis

Showing 6561-6580 of 11,007 trials

Beta-blockers in Pulmonary Arterial Hypertension

NCT02507011

The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.

Pulmonary Arterial Hypertension

University of Minnesota2 participantsStarted Jan 2016

Minneapolis, Minnesota, United States

COMPLETEDPhase 4< 1 mile

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K antagonist, such as warfarin, with or without aspirin.

Acute Coronary Syndromes

Bristol-Myers Squibb4,614 participantsStarted Jun 2015

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +623 more locations

Beta-blockers in Pulmonary Arterial Hypertension

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Find Trials by Condition in Minneapolis

A New Flexible Extended-Length Pharyngeal Airway for Deep Sedation

Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Vaccine Study for Surgically Resected Pancreatic Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

Pharmacokinetics of Anti-epileptic Drugs in Obese Children

Transvenous Lead Removal Post-Market Clinical Study

GSK2982772 Study in Subjects With Ulcerative Colitis

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Canadian Treat and Extend Analysis Trial With Ranibizumab

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Trial to Assess the Efficacy of the Comfort Plug™in Preventing Urinary Incontinence (COMFORT STUDY)

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease